Enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C-peptide levels

Journal of Internal Medicine

Volumn 241, Issue 6, 1997, Pages 493-500

  Clauson, P ^a,b   Alvarsson, M ^a   Grill, V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NOVO NORDISK A S   (Denmark)

Author keywords

C peptide; Insulin; Insulin secretion; Insulin sensitivity; Type 2 diabetes

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; ISOPHANE INSULIN; PROINSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030851920     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.1997.tb00007.x     Document Type: Article

References (15)

1. UK Prospective Diabetes Study Group. Perspectives in Diabetes. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes. A progressive disease. Diabetes 1995; 44: 1249-58.
2. Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes duration. metabolic control and β-cell function in a representative population of type 2 diabetic patients in Sweden. Diab Med 1994; 11: 794-801.
3. Weir G, Clore E, Zmachinski C, Bonner-Weir S. Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 1981; 30: 590.
4. Imamura T, Koffler M, Helderman H, Prince D, Thirlby R, Inman L et al. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes 1988; 37: 600-609.
5. Robertson R, Olsson L, Zhang H-J. Perspectives in Diabetes. Differentiating glucose toxicity from glucose desensitization. A new message from the insulin gene. Diabetes 1994; 43: 1085-9.
6. Yki-Järvinen H, Nikkilä E, Helve E, Taskinen M-R. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988; 84: 185-92.
7. Hollenbeck C, Reaven G. Treatment of patients with non-insulin-dependent diabetes mellitus: diabetic control and insulin secretion and action after different treatment modalities. Diabetic Med 1987; 4: 311-16.
8. Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-34.
9. Herbert V, Lau K, Gottlieb C, Bleicher S. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-84.
10. Bowsher R, Wolny J, Frank: B. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum. Diabetes 1992; 41: 1084-90.
11. Rijn HV, Hoekstra J, Thijssen J. Evaluation of three commercially available C-peptide kits. Ann Clin Biochem 1982; 19: 368-73.
12. Koskinen P. Nontransferability of C-peptide measurements with various commercial radioimmunoassay reagents. Clin Chem 1988; 8: 1575-8.
13. Faloona G, Unger R, Jaffe B, Behrman H, eds. Glucagon. New York: Academic Press. 1974: 317-330.
14. Andrews W, Vasquez B, Nagulesparan M. Insulin therapy in obese, non-insulin-dependent diabetes induce improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33: 634-42.
15. Klöppel G, Löhr M, Habich C, Oberholzer M, Heitz P. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Path Res 1985; 4: 110-25.